Legal & General Group PLC Point Biopharma Global Inc. Transaction History

Legal & General Group PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$6.67 - $9.71 $513 - $747	77 Added 0.14%	57,054 $380,000
Q2 2023 Aug 14, 2023	BUY	$6.86 - $10.86 $176,343 - $279,167	25,706 Added 82.2%	56,977 $516,000
Q1 2023 May 15, 2023	BUY	$6.78 - $8.1 $9,044 - $10,805	1,334 Added 4.46%	31,271 $227,000
Q4 2022 Feb 14, 2023	BUY	$5.72 - $9.78 $8,082 - $13,819	1,413 Added 4.95%	29,937 $218,000
Q3 2022 Nov 14, 2022	BUY	$7.24 - $10.31 $59,389 - $84,572	8,203 Added 40.37%	28,524 $221,000
Q2 2022 Aug 22, 2022	BUY	$5.6 - $9.5 $75,521 - $128,117	13,486 Added 197.31%	20,321 $139,000
Q4 2021 Feb 14, 2022	BUY	$4.83 - $9.75 $33,013 - $66,641	6,835 New	6,835 $38,000

20K

Ticker PNT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 104,025,000
Description
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate canc...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.